Why?Now they must conduct 10 NEW clinical trial at a cost of $100 million each (Tufts Unversity data). That is $1 billion it needs to raise by share dilution with more secondaries coming very soon. This is an unmitigated disaster for VVUS!
As they say, Qsymia was stillborn.
Exactly! I thought Vivus would only get a CRL requiring it to complete FORTRESS first. This REMS is a disaster and worse then such a CRL.
I've always though VVUS always intended to sell the rights, not necessarily the product.